#$%^&*AU2009201587B220120119.pdf#####ABSTRACT OF THE DISCLOSURE A method of chronically reducing a patient's pathological inflammation via the administration of an agent that specifically binds to an alpha-4 integrin or a dimer comprising an alpha-4 integrin is disclosed. The agent provided must have a binding affinity such that administration is sufficient to suppress pathological inflammation, and the agent is administered chronically to provide long-term suppression of pathological inflammation.14/19 Clinical Response in the CD Study 8070560 Cl' 50C4030 - -0-- Placebo 20- ' - w- 3+0 S3+3 10- 6+6 04 0 2 4 6 8 10 12 Week FIG. 6 Remission in the CD Study 5040- c 300 E20 -0- Placebo -0E- 3+0 10 - 3+3 -+ -6+6 0 0 2 4 6 8 10 12 Week FIG. 7
